Aurobindo Pharma, a major pharmaceutical company, reported a 22.5% decrease in consolidated net profit, amounting to Rs 540.40 crore, for the April-June quarter. This compares to a net profit of Rs 697.60 crore during the same period the previous year. The company’s revenue from operations reached Rs 6,850.50 crore, marking a 10% increase from the previous fiscal quarter’s Rs 6,236 crore. EBITDA saw a nearly 23% rise to Rs 1,151.4 crore, up from Rs 936.5 crore in the base quarter. The EBITDA margin expanded to 16.8%.
The company’s research and development (R&D) expenditure was at Rs 387.6 crore, accounting for 5.7% of total revenues, lower than the previous quarter’s 6.3%. In the US formulations segment, a growth of 11.2% was observed, driven by the launch of 15 products in the quarter, constituting 48.2% of consolidated revenues. Aurobindo Pharma filed 12 ANDAs, including one injectable product, with the US Food and Drug Administration during the quarter and received final approvals for 19 ANDAs.
Revenue from European formulations grew by 18.6%, comprising 26.8% of the total mix, while growth markets, accounting for 7.1% of revenue mix, grew by 12.9%. Additionally, the Active Pharmaceutical Ingredients (API) segment grew by 14% year-on-year, contributing to 15% of overall revenues in Q1.
By the end of the week, Aurobindo Pharma’s shares closed at Rs. 863.15 on the NSE, reflecting a 1.21% decrease.